Buy Immatics Ahead of H1 2027 Anzu-cel Readout; PRAME Data Could Re-rate the Stock
Immatics (IMTX) is a clinical-stage TCR developer with anzu-cel (IMA203) nearing a regulatory milestone: the Phase 3 SUPRAME program is on track for a BLA submission in H1 2027. Recent Phase 1b data showed a 56% confirmed ORR and durable responses, supporting a binary catalyst that could re-rate the $1.25B market-cap equity. This trade sets a clear…